Compare GNLX & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNLX | OPP |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 197.7M |
| IPO Year | 2023 | N/A |
| Metric | GNLX | OPP |
|---|---|---|
| Price | $4.54 | $7.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | ★ 111.5K | 108.0K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $7.26 |
| 52 Week High | $8.54 | $8.83 |
| Indicator | GNLX | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 50.45 |
| Support Level | $4.21 | $7.83 |
| Resistance Level | $4.46 | $7.96 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 83.61 | 73.68 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.